x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

The Bio Report

Levine Media Group

The Bio Report podcast, hosted by award-winning journalist Daniel Levine, focuses on the intersection of biotechnology with business, science, and policy.

science life sciences

All Episodes

21:43

Changing Drug Discovery for Neuropsychiatric...

The Bio Report ·

2022/11/23

Despite the large human and societal costs of neuropsychiatric disorders, many of these conditions have poor or no treatment options. And there has been a dearth of new mechanisms to treat major neuropsychiatric disorders for decades. PsychoGenics is seeking to change that with its unique approach to drug discovery for these conditions. Rather than rely on a target-based approach, the company has created high-throughput phenotypic screens using validated mouse models and artificial intelligence to

en

20:31

Using Virtual Reality-Guided Mindfulness to Treat...

The Bio Report ·

2022/11/17

Chronic, cancer-related pain affects between 30 and 50 percent of patients undergoing cancer treatment and more than 70 percent of patients with advanced disease. Linda Carlson, Enbridge research chair in psychosocial oncology at the University of Calgary Cumming School of Medicine, is working with digital therapeutics developer Rocket VR Health to study the potential of a virtual reality-guided mindfulness intervention program in adult cancer patients with chronic, cancer-related pain. The thinking

en

36:41

Activating the Adaptive and Innate Immune Systems to...

The Bio Report ·

2022/11/10

One reason immunotherapies can fail in cancer is that the tumor microenvironment can suppress activation of the immune system. Surface Oncology is using multiple platform technologies to discover new antibody therapies that activate both the innate and adaptive immune systems to improve how people with cancer respond to these medicines. We spoke to Rob Ross, CEO of Surface Oncology, about the tumor microenvironment, the approach Surface is taking to activate both the adaptive and innate immune

en

35:04

A Longevity Fund Focused on Young Companies

The Bio Report ·

2022/11/03

The deepening understanding of the biology of aging is giving rise to a growing list of companies that seek not only to address diseases of aging, but find ways to extend the healthy years of life. LongeVC is a venture capital firm focused on seed and early-stage investment in longevity statups. It’s also built a community of like-minded companies to support startups, as well as an acceleration program for them. We spoke to Sergey Jakimov, founding partner of LongeVC, about the firm’s approach to

en

28:10

Learning from “Elite” Responders to Develop Better...

The Bio Report ·

2022/10/27

A subset of patients treated with checkpoint inhibitors respond particularly well to these immunotherapies. These so-called “elite responders” produce antibodies that modulate immune cells in the tumor microenvironment. OncoResponse is working to discover the antibodies these elite responders produce to develop a pipeline of cancer therapies. We spoke to Bob Lechleider, chief medical officer of OncoRepsonse, about the tumor microenvironment, how his company is studying elite responders to

en

34:18

Bringing Precision Medicine to the Treatment of Obesity

The Bio Report ·

2022/10/20

Obesity rates in the United States have doubled in the past 20 years and without changes, nearly half of the adult population will be obese by 2030. Though there are many approaches to weight loss—diet and exercise, drugs, surgery—their safety and efficacy varies widely from patient to patient. Phenomix Sciences is using phenotyping to understand the type of obesity each individual has to tailor treatments that address it specifically. Based on work at the Mayo Clinic, Phenomix breaks obesity into

en

31:32

Expanding the Promise of RNA Therapies

The Bio Report ·

2022/10/13

RNA therapies and vaccines have already shown their power. Nutcracker Therapeutics is taking a nod from the high-tech sector to harness semiconductor-like biochips and microfluidic engineering to create a fully automated platform to increase the speed and scale at which RNA therapies can be discovered, developed, and manufactured. It is developing multimodal RNA therapies which serves as an RNA cocktail to attack multiple disease mechanisms at once. We spoke to Geoff Nosrati, chief business officer

en

29:13

Triggering a Systemic Immune Response Against Cancer

The Bio Report ·

2022/10/06

Immune checkpoint inhibitors are transforming cancer care, but still have low response rates in most solid tumors. When cancer spreads to the liver, it can render immunotherapies ineffective because of the large number of immune-suppressive macrophages that are present there. Teclison has developed platform technology that chokes off tumors and activates the immune system against the cancer. The company said its technology can significantly enhances the therapeutic benefit of immunotherapies and can

en

25:57

Targeting RNA Dysregulation in Cancer

The Bio Report ·

2022/09/29

Inspirna is putting RNA biology to work to address difficult to treat cancers that affect large numbers of people, such as colorectal cancer, small cell lung cancer, and non-small cell lung cancer. Its platform technology is being used to discover the underlying drivers of cancer that can be drugged by both small molecules and biologics to address RNA dysregulation. We spoke to Masoud Tavazoie, co-founder and CEO of Inspirna, about the role RNA dysregulation plays in certain cancers, Inspirna’s

en

37:53

Building a Pipeline of Next-Generation Kinase Inhibitors

The Bio Report ·

2022/09/22

Kinase inhibitors have become staples in the arsenal to battle cancer. These medicines can disrupt the cell signaling that drives the growth and spread of tumors. There are more than 30 approved kinase inhibitors today, but they often have dose limiting toxicities, in part because they often lack specificity and can have activity against multiple kinases at once. Blueprint Medicines is seeking to develop next-generation kinase inhibitors that are highly selective to treat genomically-defined cancers

en

42:06

Rethinking How Cell and Gene Therapies Are Made to...

The Bio Report ·

2022/09/15

Cell and gene therapies offer great promise for treating, preventing, or curing serious health issues like cancer, genetic disorders, immunodeficiencies, and rare diseases. Nevertheless, the complexity and costs of producing and delivering these personalized medicines creates barriers to patients benefiting from their potential. Orgenesis is seeking to change the business model around cell and gene therapies through its Point-of-Care Platform, which it says can lower the cost, accelerate

en

26:47

Developing Next-Generation Radiopharmaceuticals

The Bio Report ·

2022/09/08

Radiopharmaceuticals have long been shown to be effective at killing cancers, but often damage healthy cells because they are so toxic. Convergent Therapeutics has developed platform technology that takes advantage of the power of radiopharmaceuticals, but links them to targeting mechanisms, such as monoclonal antibodies and ligands, to deliver them in a precise and highly targeted ways. Its lead experimental therapy is an actinium-linked monoclonal antibody that targets prostate-specific membrane

en

28:24

Why Great Science and Data Aren’t Enough

The Bio Report ·

2022/09/01

Whether it’s capturing the imagination of a venture capitalist, enticing a potential partner, or attracting talent, CEOs need to be able to tell their company’s story effectively. In his new book “Winners Have a Story,” Giuseppe Marzio discusses how CEOs can turn complex science and technology into compelling tales. Marzio, who worked as a scientist in biopharma before launching a communications agency, comes to his interest in storytelling honestly. Growing up with a love for the cinema, he had

en

26:40

Targeting Sugars that Let Cancers Evade the Immune...

The Bio Report ·

2022/08/25

It’s been understood for more than 60 years that cancer cells overproduce sugars on their surface. More recently it’s been discovered that these sugars can help cancer cells evade the immune system. Palleon Pharmaceuticals is developing immunotherapies that work by targeting these cell surface sugars and make them vulnerable to attack. We spoke to David Feltquate, chief medical officer of Palleon, about the potential to harness glycobiology to treat cancer, how the company is working to modulate

en

18:52

Engineering Stem Cells to Withstand Targeted Therapies

The Bio Report ·

2022/08/18

Current treatment of acute myeloid leukemia generally consists of chemotherapy followed by a hematopoietic stem cell transplant to eliminate any remaining cancer cells from the bone marrow. Even though outcomes remain poor with around 40 percent of transplanted patients experiencing cancer relapse, and patients who do relapse having two-year survival rates of less than 20 percent, the approach has changed little in 40 years. One reason is that newly transplanted patients are unable to receive

en

24:15

Targeting a Convergence of Signaling Pathways that...

The Bio Report ·

2022/08/11

In cancer, the rigorous translational machinery of the human body goes haywire, causing an overproduction of proteins that fuel the growth and spread of tumors, as well as enabling them to evade the immune system. Effector Therapeutics is developing a new class of cancer therapies called selective translation regulator inhibitors, or STRIs, that can inhibit the production of proteins that drive a cancer. We spoke to Steve Worland, president and CEO of Effector, about the company’s new class of

en

21:19

Moving from Preservation to Restoration with...

The Bio Report ·

2022/08/04

While cell therapies hold great promise for not only halting the progression of degenerative disease but potentially restoring the body, cost has remained a barrier. Lineage Cell Therapeutics is developing allogenic cell therapies that don’t rely on modifying a patient’s own cells, making them scalable and less costly than autologous ones. At the end of last year, the company entered into a partnership with Genentech to develop and commercialize OpRegen, its experimental cell therapy for dry

en

21:27

Using Gene Therapies to Treat Chronic, Inflammatory...

The Bio Report ·

2022/07/28

A broad range of serious diseases involve chronic inflammation, which causes both pain and progressive damage. Xalud Therapeutics is developing a locally-delivered, non-viral gene therapy that is designed to harness the ability of interleukin-10 to regulate the immune system and restore homeostasis. The company’s lead indication is in osteoarthritis We spoke to Diem Nguyen, CEO of Xalud, about the role inteleukin-10 plays in regulating multiple pathways in the immune system, Xalud’s gene therapy,

en

38:27

Unlocking the Full Potential of Antibody Therapies

The Bio Report ·

2022/07/21

Traditional antibody discovery depends, in part, on a bit of good fortune that banks on the hope that either screening antibody libraries or exposing an organism to an antigen will result in the discovery of a compelling therapy. Yanay Ofran, CEO of Biolojic Design, says the problem with this approach is that it ignores many of the performance-related aspects of an antibody beyond its ability to bind to a target. His company’s AI platform for antibody discovery seeks to capitalize on the full

en

22:04

Combatting Superbugs and Emerging Viruses

The Bio Report ·

2022/07/14

The rise of antibiotic resistance and the threat of emerging viral pathogens have created global public health threats. Recce Pharmaceuticals is developing a new class of synthetic anti-infectives that it says can overcome the hyper-cellular mutation of bacteria and viruses. What’s more, the company says their potency doesn’t diminish even with repeated use. We spoke to James Graham, CEO of Recce, about its synthetic anti-infectives, how they work, and why they can be used repeatedly against a broad

en

316 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter